ORIGINAL RESEARCH article

Front. Glob. Women’s Health, 21 July 2023

Sec. Contraception and Family Planning

Volume 4 - 2023 | https://doi.org/10.3389/fgwh.2023.1095112

Women's preferences for a new contraceptive under development: an exploratory study

  • 1. Divisions of Family Planning & Clinical Research, Department of Obstetrics and Gynecology, Washington University in St. Louis School of Medicine, St. Louis, MO, United States

  • 2. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Cincinnati College of Medicine, Cincinnati, OH, United States

  • 3. Department of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy in St. Louis, St. Louis College of Pharmacy, St. Louis, MO, United States

Abstract

Objective:

Currently available contraceptive methods do not meet the needs of all users. We sought to explore preferences of potential end-users regarding an on-demand, non-hormonal female contraceptive currently under development, using a web-based survey.

Study design:

We recruited respondents for an exploratory survey via web link on Amazon Mechanical Turk (MTurk). Individuals were eligible if they were 18–44 years of age, identified as cis-gender female, were English-speaking, not pregnant, and had used barrier contraception previously. Respondents provided demographic characteristics and a basic reproductive history. We then provided a brief description of the potential contraceptive. Respondents were asked about their interest in the proposed contraceptive and preferences for method attributes.

Results:

A total of 500 respondents completed the survey. Three-quarters of respondents were <35 years of age and 48.2% were currently using a barrier contraceptive method. Three-fourths of respondents (73.8%) expressed interest in using the contraceptive under development. The majority wanted the method to be small (≤2 inches), rod-shaped, and low cost (<$5 per use). More than half (59.4%) said it was important to be able to use the method without partners’ knowledge. The most reported potential concerns were vaginal irritation (51.6%) and lack of effectiveness (46.4%). Sixty percent of respondents were confident they could use the method correctly.

Discussion:

Available contraceptive methods lack attributes preferred by some users. Development of new contraceptives frequently does not involve end-user input early in the development process. Individuals in this sample displayed interest in the proposed contraceptive and expressed preferences that can inform the further development of this method.

1. Introduction

Contraception is a cornerstone of reproductive health. However, approximately 30% of reproductive-age US women who do not desire pregnancy were not using contraception at their last sexual encounter (1). There are several coitally-dependent, or on-demand, non-hormonal methods available in the United States including male and female condoms, diaphragms and cervical caps, spermicides, and contraceptive gels (2). While 12.9% of contraceptive users in the United States rely on male condoms as their primary contraceptive method, the proportion that relies on other coitally-dependent methods is less than 1% (3). Male condoms may be used in combination with another method: approximately one-quarter of reproductive-age women reported using a male condom during their most recent sexual intercourse (4).

Not all available on-demand contraceptives possess the attributes users deem most important, including effectiveness, low risk of side effects, affordability, ease of access and use, and female-controlled (5). Prior studies have reported one-third of women feel that contraceptive use only at the time of sex is “extremely important” and more than two-thirds of women prefer to determine if and when contraception is used (5, 6). While widely used, male condoms do not have all the attributes many individuals value in a contraceptive method, such as being user-controlled. On-demand, female-controlled methods, such as female condoms and spermicides also have barriers to use; patients frequently report female condoms are difficult or uncomfortable to insert, interfere with sexual experience, and partners object to the method (7, 8). Moreover, more than 50% of women prefer methods that can be concealed from a partner (5, 6). Currently available methods that are more difficult for a partner to detect, such as spermicides, can increase the risk of vaginal irritation, allergic reactions, and sexually transmitted infection (STI) acquisition (2).

The gap in available contraception with preferred attributes may be filled with new contraceptive technologies, and input from end users regarding their preferences can optimize a new method development. We sought to explore the preferences of potential end users regarding an on-demand, non-hormonal method of contraception currently under development.

2. Materials and methods

We recruited a convenience sample of respondents through Amazon Mechanical Turk (MTurk). MTurk is a web service frequently used for research recruitment in the social sciences (9). Compared to other in-person convenience sampling tools, MTurk has been shown to generate a sample more representative of the general U.S. population (10). The platform allows each worker to complete a task only once, ensuring unique respondents. MTurk workers review a list of available tasks and select tasks to complete. Worker who selected our task clicked a link that redirected them to the survey in Research Electronic Data Capture tools (REDCap) hosted at Washington University (11, 12). REDCap is a secure, HIPAA compliant, web-based application. We did not collect any protected health information from respondents.

Individuals were eligible to participate if they lived in the United States, were of reproductive age (18–44 years) English-speaking, identified as a cis-gender female, were not pregnant, and had previously used barrier contraception. At the halfway point of recruitment (n = 250 enrolled), we limited enrollment to individuals currently using a barrier method and excluded individuals who had undergone surgical sterilization (tubal ligation or hysterectomy) to increase the sample of individuals who might be potential users of the proposed contraceptive. Eligible individuals reviewed a consent information sheet prior to beginning the survey. They were given the option to exit the browser window if they did not wish to participate. The project was approved by the Washington University in St. Louis School of Medicine Institutional Review Board prior to recruitment.

Eligible individuals completed the survey through a web link. Survey responses were verified by including random attention test questions alongside survey questions. Respondents who completed the survey with accurate attention test responses were compensated with a $2.14 deposit into their Amazon Payments account determined based on minimum wage calculations relative to survey length and time to completion (13).

The survey began with screening questions to determine eligibility, followed by questions to gather respondent characteristics and a brief reproductive history. We asked respondents about the primary reason for prior or current use of male and/or female condoms (if applicable), STI history, and whether they had ever felt pressured by their partner to not use contraception to prevent pregnancy or STIs.

Following these questions, we showed respondents the following prompt introducing the novel contraceptive method currently in development, “A new type of birth control is being designed. You would put it in the vagina before having sex. The birth control would start as a fabric-like, delicate material and dissolve into a gel that would protect against pregnancy and sexually transmitted infections. It is a method you could use without your partner knowing.” After reading the prompt, we asked respondents if they would be interested in using the novel contraceptive. Subsequent questions elicited feedback on product characteristics such as preferred size of the product, largest size the respondent would be comfortable with, how quickly they would expect the product to work, how long they would expect the effects to last, how much they would be willing to pay per use, the importance of using the method without the partner knowing, where they would expect to be able to purchase the product, and concerns they had about using it. We showed respondents photos of a tampon, suppository, contraceptive film, and spermicide next to a quarter coin for scale (Figure 1) and asked how much they would like a new method in the different shapes on a 5-point Likert scale from 1 (strongly dislike) to 5 (strongly like).

Figure 1

We performed statistical analysis using SPSS, Version 27 (IBM Corp., Armonk, NY). We used descriptive statistics to characterize the respondents as well as their responses regarding features and characteristics of the proposed new contraceptive method and potential concerns and confidence about using the proposed new method.

3. Results

We administered the surveys from August 2020 to September 2020. A total of 3,406 individuals opened the survey; of these 825 were eligible (24.2%). Of the eligible individuals, 200 did not complete the survey and 125 failed the attention checks, leaving a final sample of 500 individuals (60.6%). Respondents were predominantly white (74.4%) and non-Hispanic (83.8%). The majority were ages 25–34 (69.8%). Current barrier method use was reported by 48.2%. Almost one third (29.0%) had a history of a STI and 42.0% reported a prior unintended pregnancy. Half the respondents (51.2%) reported having previously been pressured by a partner to not use contraception (Table 1).

Table 1

CharacteristicTotal
N = 500
Age, median (IQR)30 (25–34)
Hispanic81 (16.2)
Race
 American Indian, Native American5 (1.0)
 Asian or Pacific Islander14 (2.8)
 Black, African American97 (19.4)
 White372 (74.4)
 Other, Multiracial6 (1.2)
 Did not report6 (1.2)
Any history of barrier method use342 (68.4)
Current barrier method use241 (48.2)
History of unintended pregnancy
Yes210 (42.0)
No290 (58.0)
History of STI
Yes145 (29.0)
No327 (65.4)
Unsure28 (5.6)
Reason for using male condoma
Mostly pregnancy prevention117 (49.6)
Mostly STI prevention51 (21.6)
Both68 (28.8)
Uses tampons with period
Yes331 (66.2)
No169 (33.8)
Pressured by partner to not use contraception
Yes256 (51.2)
No244 (48.8)
Pressured by partner to not use contraception to prevent STIs
Yes220 (44.0)
No280 (56.0)

Demographic and reproductive characteristics of respondents.

a

Denominator is 236 that reported ever using a male condom.

Nearly three-quarters (73.8%) of respondents reported interest in using the proposed contraceptive while 9.6% were unsure. While preferences about contraceptive attributes varied, a method two inches or smaller, effective within five minutes, lasting at least 3–6 h, cost less than $5 per use, and could be used without a partner's knowledge was preferred by over half of the sample (Table 2). Two-thirds of respondents reported using tampons with their period and a tampon shape was the most preferred of the presented options for the new contraceptive (Figure 2). Approximately half of respondents expected that were this method available, they could obtain it at a retail location such as a drug store, supermarket, or large retail store (Table 2).

Table 2

Product feedbackTotal
N = 500
Interested in using method
Yes369 (73.8)
No83 (16.6)
Unsure48 (9.6)
Comfortable placing in vagina without applicator
Yes342 (68.4)
No99 (19.8)
Unsure59 (11.8)
Preferred product size
Smaller than 1 inch133 (26.6)
1–2 inches269 (53.8)
3 inches or larger98 (19.6)
Largest product size would use
Smaller than 1 inch102 (20.4)
1–2 inches247 (49.4)
3 inches or larger151 (30.2)
How quickly would you EXPECT the product to work?
Immediately77 (15.4)
Within 5 min250 (50.0)
Within 10 min143 (28.6)
Within 15 min30 (6.0)
How long would you expect the effects of this product to last?
1–2 h120 (24.0)
3–6 h307 (61.4)
7–12 h51 (10.2)
More than 12 h22 (4.4)
How much would you be willing to pay per use?
< $140 (8.0)
< $3144 (28.8)
< $5206 (41.2)
< $1081 (16.2)
< $1529 (5.8)
Important to use without partner knowing
Yes296 (59.2)
No172 (34.4)
Unsure32 (6.4)
Where would you expect to be able to buy the product?
Drug store264 (52.8)
Grocery store or supermarket236 (47.2)
Large retail store226 (45.2)
Clinic or health center190 (38.0)
Prescription from doctor171 (34.2)
Gas station100 (20.0)

Participant feedback on attributes of a proposed novel contraceptive.

Figure 2

Respondent concerns about using the contraceptive were most commonly about vaginal irritation (51.6%) and lack of effectiveness at preventing pregnancy (46.4%) (Figure 3). The majority of respondents (59.8%) were confident they could use the proposed contraceptive correctly, only 2.0% of respondents were “not at all confident” they could use the contraceptive correctly.

Figure 3

4. Discussion

In this study, over two-thirds of the respondents expressed interest in using the proposed, on-demand contraceptive. When asked about potential characteristics of the method, respondents preferred the contraceptive to be similar in shape and size to a tampon and low in cost. Over half the respondents said it was important to be able use the method without their partner knowing, a significant finding given that nearly half of respondents reported prior experience with partner coercion to not use contraception. Respondents’ most common concerns about use of the proposed contraceptive were vaginal irritation and lack of effectiveness.

Side effects and effectiveness have been previously shown to be principal considerations for individuals when choosing a contraceptive method (5, 14, 15). In two studies conducted in low- and middle-income countries, health concerns, including concerns about side effects, were the most common reason for contraceptive nonuse (14, 15). In three different U.S. surveys, contraceptive effectiveness was commonly identified as “extremely important” by greater than 80% of respondents. These surveys also found that a low risk of side effects was also important to approximately 75% of respondents (5, 6, 16). Although our respondents also identified contraceptive effectiveness and potential side effects as important concerns, the overall percentages who cited these concerns were lower in our study compared to previous studies.

Prior studies have shown that partner opinion influences likelihood of contraceptive use (5, 8, 14, 15, 17, 18). A study of South African university students found that women were more likely to use female condoms if their partner had a “positive attitude” toward the condoms (17). Another international study identified partner opposition as a reason for contraceptive nonuse (15). Users may prefer independent control of contraception and methods that cannot be detected by partners. In a 2012 survey of U.S. women at risk of unintended pregnancy, 70% of respondents identified the ability to control the use of contraception as an “extremely important” contraceptive feature and an “undetectable” contraceptive method was classified as “extremely important” by 57% of respondents (5). A study of California adolescents found that about 60% of respondents preferred that their contraceptive method was “partner-independent” (16). A diverse group of respondents from six states found control over method use (71%), responsibility for method use (62%) and imperceptible method (55%) to be “extremely important.” Black and Hispanic women were more likely to rate these features as “extremely important” than their white counterparts (6). Though our findings are similar to prior studies, we found a smaller majority of respondents who preferred a method which could not be detected by their partner. Because our sample was predominantly white and non-Hispanic, this difference may be explained by racial and ethnic variations in contraceptive preferences (6).

Although some studies have assessed women's contraceptive preferences related to the attributes of existing methods, there has been limited end-user involvement in the development of new contraceptives. End-user feedback has been shown to assist in development of effective reproductive health tools, such as contraceptive decision aids (19). However, end user input into new contraceptive development, especially early in the development process, has been limited. Greater emphasis has been placed on technical feasibility rather than user preference, particularly during the development of non-hormonal methods (20, 21). Thus, the National Institutes of Health has made it a priority to include end-user input early in the contraceptive development process (22). Additionally, the FDA and international medical device regulatory authorities require the incorporation of user input into the design process (2325). Our survey aimed to identify user preferences for this contraceptive under development with a focus on design features, such as size, shape, time to efficacy and length of efficacy which may impact willingness to use the method.

Strengths of this study included a broad sample—we enrolled respondents from across the United States via MTurk. The use of MTurk allows for broader recruitment of respondents, including outside of clinical or research settings. The MTurk platform also permitted continued recruitment throughout the COVID-19 pandemic. Respondents were sexually active, reproductive-age females at risk of STIs and unintended pregnancy, which is the segment of the population most likely to use barrier contraception. Furthermore, three-quarters of our sample was less than 35 years old, which is appropriate given that 25–34-year-old women not seeking pregnancy have the highest rate of contraceptive use and 20–39-year-old women have the highest rate of condom use compared to other age groups (26, 27).

Our study does have some limitations. Only English-speaking respondents in the United States, most of whom had used a barrier method previously, were eligible. In addition, our sample was predominantly white and non-Hispanic. Therefore, these findings may not be generalizable to other potential users. We also changed our eligibility criteria after half the respondents completed the survey to better identify respondents who could be potential end users which could further limit generalizability. The data presented relies on respondents’ self-report which is subject to self-report bias. This may be more likely for responses to sensitive questions which the survey included. We asked respondents about a product which has not yet been developed, which could result in an overestimation of the likelihood of real-world use. We also stated in the description of the proposed contraceptive it could be used without partners’ knowledge, which may have biased respondents towards identifying this as an important attribute, although our findings are similar to other studies. Several studies have raised potential limitations of the use of MTurk, particularly related to the characteristics of MTurk samples (2830). MTurk respondents tend to be more politically liberal, have higher education levels, less religiosity, and lower life satisfaction (10). Furthermore, participation in the MTurk platform requires internet access, use of Amazon, and awareness of the platform's existence.

Our results provide further insights about user preferences for contraceptive attributes and design. Understanding the importance of a familiar shape and insertion technique could improve users’ comfort with a new method. Incorporating end users’ feedback early in the design process is critical for successful device development. Respondents in this sample indicated an interest in hypothetical product with potential to be effective at preventing pregnancy, sold at low cost, and used with few side effects. The development of this novel contraceptive could further expand individuals’ choices ultimately improving contraceptive uptake and continuation.

Statements

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors upon request, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Washington University Institutional Review Board, Human Research Protection Office. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

TM, RP, EH, MT, and GP contributed to study conceptualization and design. TM and RP contributed to data collection. TM, SC, and RP contributed to data analysis. SC and RP wrote the initial draft of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This research was supported in part by a Strategic Collaborative Grant from the University of Cincinnati “Creating Our Third Century” and the Eunice Kennedy Shriver National Institute of Child Health and Human Development under Award Number R33HD099748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest

TM serves on a data safety monitoring board for phase 4 safety studies of Bayer contraceptive products.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor KN declared a past co-authorship with the author(s) MAT.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1.

    ZapataLBPazolKCurtisKMKaneDJJatlaouiTCFolgerSGet alNeed for contraceptive services among women of reproductive age—45 jurisdictions, United States, 2017–2019. MMWR Morb Mortal Wkly Rep. (2021) 70(25):910. 10.15585/mmwr.mm7025a2

  • 2.

    BrittonLEAlspaughAGreeneMZMcLemoreMR. CE: an evidence-based update on contraception. Am J Nurs. (2020) 120(2):2233. 10.1097/01.NAJ.0000654304.29632.a7

  • 3.

    Contraceptive Use in the United States by Method New York, NY: Guttmacher Institute (2021). Available at:https://www.guttmacher.org/fact-sheet/contraceptive-method-use-united-states#

  • 4.

    CopenC. Condom use during sexual intercourse among women and men aged 15–44 in the United States: 2011–2015 national survey of family growth. Natl Health Stat Report. (2017) 105:118.

  • 5.

    LessardLNKarasekDMaSDarneyPDeardorffJLahiffMet alContraceptive features preferred by women at high risk of unintended pregnancy. Perspect Sex Reprod Health. (2012) 44(3):194200. 10.1363/4419412

  • 6.

    JacksonAVKarasekDDehlendorfCFosterDG. Racial and ethnic differences in women’s preferences for features of contraceptive methods. Contraception. (2016) 93(5):40611. 10.1016/j.contraception.2015.12.010

  • 7.

    ChoiKHRobertsKJGomezCGrinsteadO. Facilitators and barriers to use of the female condom: qualitative interviews with women of diverse ethnicity. Women Health. (1999) 30(1):5370. 10.1300/J013v30n01_04

  • 8.

    EldridgeGDLawrenceJSLittleCEShelbyMCBrasfieldTL. Barriers to condom use and barrier method preferences among low-income African-American women. Women Health. (1995) 23(1):7389. 10.1300/J013v23n01_05

  • 9.

    MortensenKHughesTL. Comparing Amazon’s mechanical turk platform to conventional data collection methods in the health and medical research literature. J Gen Intern Med. (2018) 33(4):5338. 10.1007/s11606-017-4246-0

  • 10.

    BerinskyAJHuberGALenzGS. Evaluating online labor markets for experimental research: amazon.com’s mechanical Turk. Polit Anal. (2017) 20(3):35168. 10.1093/pan/mpr057

  • 11.

    BrawleyAMPuryCLS. Work experiences on MTurk: job satisfaction, turnover, and information sharing. Comput Human Behav. (2016) 54:53146. 10.1016/j.chb.2015.08.031

  • 12.

    HarrisPATaylorRMinorBLElliottVFernandezMO'NealLet alThe REDCap consortium: building an international community of software platform partners. J Biomed Inform. (2019) 95:103208. 10.1016/j.jbi.2019.103208

  • 13.

    HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. (2009) 42(2):37781. 10.1016/j.jbi.2008.08.010

  • 14.

    SedghGAshfordLSHussainR. Unmet need for contraception in developing countries: Examining women’s reasons for not using a method. New York: Guttmacher Institute; (2016).

  • 15.

    MoreiraLREwerlingFBarrosAJDSilveiraMF. Reasons for nonuse of contraceptive methods by women with demand for contraception not satisfied: an assessment of low and middle-income countries using demographic and health surveys. Reprod Health. (2019) 16(1):148. 10.1186/s12978-019-0805-7

  • 16.

    WalkerAWSternLCipresDRodriguezAAlvarezJSeidmanD. Do adolescent women’s contraceptive preferences predict method use and satisfaction? A survey of northern California family planning clients. J Adolescent Health. (2019) 64(5):6407. 10.1016/j.jadohealth.2018.10.291

  • 17.

    MantellJEExnerTMBaiDLeuC-SBeksinskaMMabudeZet alPerceived male partner attitudes toward the female condom predict female university students’ use of the female condom. Int J STD AIDS. (2020) 31(8):75362. 10.1177/0956462420912986

  • 18.

    LavelanetAFRalphJATiADuggarajuAYehPT. A systematic review exploring the contraception values and preferences of sex workers, transmasculine individuals, people who inject drugs, and those living in humanitarian contexts. Contraception. (2022) 111:32–8. 10.1016/j.contraception.2021.06.008

  • 19.

    HooiveldTMolenaarJMvan der HeijdeCMMeijmanFJGroenTPVonkP. End-user involvement in developing and field testing an online contraceptive decision aid. SAGE Open Med. (2018) 6:2050312118809462. 10.1177/2050312118809462

  • 20.

    CallahanRLMehtaNJNandaKKopfGS. The new contraceptive revolution: developing innovative products outside of industry. Biol Reprod. (2020) 103(2):15766. 10.1093/biolre/ioaa067

  • 21.

    HemmerlingAChristopherEYoung HoltB. Towards a roadmap to advance non-hormonal contraceptive multipurpose prevention technologies: strategic insights from key stakeholders. Biol Reprod. (2020) 103(2):28998. 10.1093/biolre/ioaa092

  • 22.

    Contraception Research Branch (CRB). Eunice Kennedy Shriver National Institute of Child Health and Human Development (2022); Available at: https://www.nichd.nih.gov/about/org/der/branches/crb

  • 23.

    Code of Federal Regulations. 21CFR820.30. Sect. 820.30 (2021).

  • 24.

    PriviteraMBEvansMSoutheeD. Human factors in the design of medical devices—approaches to meeting international standards in the European union and USA. Appl Ergon. (2017) 59:25163. 10.1016/j.apergo.2016.08.034

  • 25.

    ShahSGRobinsonI. Benefits of and barriers to involving users in medical device technology development and evaluation. Int J Technol Assess Health Care. (2007) 23(1):1317. 10.1017/S0266462307051677

  • 26.

    KavanaughMLPliskinE. Use of contraception among reproductive-aged women in the United States, 2014 and 2016. F&S Reports. (2020) 1(2):8393. 10.1016/j.xfre.2020.06.006

  • 27.

    DanielsKAbmaJC. Current Contraceptive Status Among Women Aged 15–49: United States, 2017–2019. NCHS Data Brief, no 388. Hyattsville, MD: National Center for Health Statistics (2020).

  • 28.

    ChandlerJRosenzweigCMossAJRobinsonJLitmanL. Online panels in social science research: expanding sampling methods beyond mechanical Turk. Behav Res Methods. (2019) 51(5):202238. 10.3758/s13428-019-01273-7

  • 29.

    HuffCTingleyD. “Who are these people?” evaluating the demographic characteristics and political preferences of MTurk survey respondents. Research Politics. (2015) 2(3):2053168015604648. 10.1177/2053168015604648

  • 30.

    StoneAAWalentynowiczMSchneiderSJunghaenelDUWenCK. MTurk participants have substantially lower evaluative subjective well-being than other survey participants. Comput Human Behav. (2019) 94:18. 10.1016/j.chb.2018.12.042

Summary

Keywords

contraception, contraceptive preferences, contraceptive development, MTurk, nonhormonal

Citation

Madden T, Cohen SY, Paul R, Hurley EG, Thomas MA and Pauletti G (2023) Women's preferences for a new contraceptive under development: an exploratory study. Front. Glob. Womens Health 4:1095112. doi: 10.3389/fgwh.2023.1095112

Received

10 November 2022

Accepted

06 July 2023

Published

21 July 2023

Volume

4 - 2023

Edited by

Kavita Nanda, Family Health International 360, United States

Reviewed by

Peter Ouma Okuma, Government of Kenya, Kenya Alida Gertz, WellStar Health System, United States

Updates

Copyright

*Correspondence: Tessa Madden

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics